CD147 and MCT1‐potential partners in bladder cancer aggressiveness and cisplatin resistance

Publisher： John Wiley & Sons Inc

E-ISSN： 1098-2744|54|11|1451-1466

ISSN： 0899-1987

Source： Molecular Carcinogenesis, Vol.54, Iss.11, 2015-11, pp. : 1451-1466

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MiR‐5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6

By  

Molecular Carcinogenesis, Vol. 57, Iss. 3, 2018-03 ,pp. : 419-428

John Wiley & Sons Inc

Access to resources Recommend Favorite

ZEB1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

By  

EMBO Molecular Medicine, Vol. 7, Iss. 6, 2015-06 ,pp. : 831-847

John Wiley & Sons Inc

Access to resources Recommend Favorite

Crosstalk between VEGF and MTA1 signaling pathways contribute to aggressiveness of breast carcinoma

By  

Molecular Carcinogenesis, Vol. 54, Iss. 5, 2015-05 ,pp. : 333-350

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pro‐inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF‐κB activation

By  

Molecular Carcinogenesis, Vol. 57, Iss. 2, 2018-02 ,pp. : 235-242

John Wiley & Sons Inc

Access to resources Recommend Favorite

BAG3‐dependent expression of Mcl‐1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922

By  

Molecular Carcinogenesis, Vol. 57, Iss. 2, 2018-02 ,pp. : 284-294

John Wiley & Sons Inc

Access to resources Recommend Favorite